---
schema_version: "secwatch.filing_event.v1"
accession: "0000310764-21-000144"
form_type: "8-K"
ticker: "SYK"
cik: "0000310764"
company_name: "STRYKER CORP"
filed_at: "2021-10-28T23:59:59+00:00"
generated_at: "2026-06-28T17:01:04.942617+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Stryker Q3: adj EPS $2.20 (+2.8%); organic sales +4.5%; China impairment $105M; guidance revised

## Summary
- Net sales $4.2B, +11.3% vs 2020; organic net sales +4.5% vs 2020 and +8.4% vs 2019.
- Reported EPS $1.14 (down 30.1%); adjusted EPS $2.20 (up 2.8%) due to $105M impairment.
- $105M impairment for China trauma/joint replacement VBP price reductions impacting Orthopaedics.
- 2021 outlook: organic sales growth 7%-8% from 2019; adj EPS $9.08-$9.15.

## SEC filing metadata
- accession: 0000310764-21-000144
- form_type: 8-K
- ticker: SYK
- cik: 0000310764
- company_name: STRYKER CORP
- filed_at: 2021-10-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/310764/000031076421000144/0000310764-21-000144-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/310764/000031076421000144/syk-20211028.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000310764-21-000144
- JSON: https://secwatch.observer/filing/0000310764-21-000144.json
- Plain text: https://secwatch.observer/filing/0000310764-21-000144.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.